TNYA vs TRVI

Tenaya Therapeutics, Inc. vs Trevi Therapeutics, Inc. — Valuation Comparison 2026

TNYA

Biotechnology
Tenaya Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
30
LOW
Price
$0.80
Last close
Models
8/13
Active
VS

TRVI

Biotechnology
Trevi Therapeutics, Inc.
Quality
4.2
out of 10
Value Trap
30
LOW
Price
$14.45
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType TNYA Fair ValueTNYA Upside TRVI Fair ValueTRVI Upside
Bayesian DCF Intrinsic $0.40 -50.0% $4.39 -69.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.04 -94.6% $0.40 -97.3%
Dynamic NAV Asset-Based $0.79 -1.2% $1.06 -92.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for TNYA vs TRVI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TNYA vs TRVI — Which Stock Is More Undervalued?

TRVI scores higher with a 4.2/10 quality rating vs TNYA's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Tenaya Therapeutics, Inc. (TNYA) and Trevi Therapeutics, Inc. (TRVI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TNYA currently trades at $0.80 with a QOC of 4.1/10, while TRVI trades at $14.45 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).

TNYA
View Full Tenaya Therapeutics, Inc. Analysis →
TRVI
View Full Trevi Therapeutics, Inc. Analysis →